1. Cost-effectiveness: Subcutaneous immunotherapy (SCIT) with tree pollen (TP), grass pollen (GP), house dust mites (HDM) or combinations is cost-effective compared to usual care (UC) only. 2. Clinical effectiveness: SCIT with more than one…
ID
Bron
Verkorte titel
Aandoening
EN:
allergic rhinitis
immunotherapy
adult
costs and cost analyses
NL:
allergische rhinitis
immunotherapie
volwassenen
kosten-effectiviteit
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
1. Cost-effectiveness: The costs per successfully treated patient, where success is based on a global assessment of efficacy by the patient after the allergen peak period in year 2 for the group that starts in 2009 and year one for the group that starts in 2010. The global assessment of efficacy is based on a rating of general improvement on a 6-point ordinal scale (much worse, a little worse, no change, a little better, much better, completely recovered). The response options “much better” and “completely recovered” define treatment success. In case of multiple allergens treatment success is defined as follows: the response option “much better” or “completely recovered” for at least one allergen and for the remaining allergens “no change”, “better”, “much better” or “completely recovered;<br>
2. Clinical effectiveness:<br>
A. The mean daily total rhinitis symptom score in the first year for multi-sensitized patients;<br>
B. Daily symptom scores will be recorded during the peak exposure periods: tree pollen April 1 - May 15; grass pollen May 15 - June 30; house dust mite September 1 - October 30. (If the patient is treated with two or three allergens, symptom scores will be recorded during two or three periods) For tree and grass pollen: only days with sufficient exposure will be analyzed;<br>
C. The intensity of 4 rhinitis symptoms (nasal blockage, watery runny nose, sneezing, itching nose) will be subjectively assessed by the patient on a scale grading from 0 = no complaints to 3 = serious complaints.
Achtergrond van het onderzoek
N/A
Doel van het onderzoek
1. Cost-effectiveness: Subcutaneous immunotherapy (SCIT) with tree pollen (TP), grass pollen (GP), house dust mites (HDM) or combinations is cost-effective compared to usual care (UC) only.
2. Clinical effectiveness: SCIT with more than one allergen is clinically more effective - with respect to symptom improvement, medication reduction and health related quality of life - than usual care.
Onderzoeksopzet
N/A
Onderzoeksproduct en/of interventie
Subcutaneous immunotherapy with tree pollen and/or grass pollen and/or house dust mite extract (Alutard SQ 197/293/503; ALK-Abello) + usual care vs usual care only.
Algemeen / deelnemers
Esther Röder
ErasmusMC
Section of Allergology
Dept of Internal Medicine
Rotterdam 3000 CA
The Netherlands
+31 (0)10 7033981
e.roder@erasmusmc.nl
Wetenschappers
Esther Röder
ErasmusMC
Section of Allergology
Dept of Internal Medicine
Rotterdam 3000 CA
The Netherlands
+31 (0)10 7033981
e.roder@erasmusmc.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. 18-45 years;
2. Clinically relevant moderate to severe allergic rhinitis due to a sensitization for one, two or three of the following
allergens: tree pollen (TP), grass pollen (GP) and/or house dust mite (HDM). For each allergen (TP, GP, HDM) the following 3 criteria are evaluated. A sensitization for an allergen is considered clinically relevant and the rhinitis moderate-severe if:
A. Specific IgE >= 0.7 kU/l (Phadia);
B. Retrospective total symptom score >=4: participants will score 4 nose symptoms (sneezing, itching nose, watery running nose, nasal blockage) during the previous peak exposure period (TP April 1-May 15; GP May 15- June 30; HDM September 1-October 31) on a 0-3 scale (0=none, 1=mild, 2=moderate, 3=severe; maximum total score=12);
C. The presence of >=1 of the following complaints due to rhinitis during the previous season: sleep disturbance; impairment of daily activities; leisure and/or sport; impairment of school or work; troublesome symptoms.
3. Signed informed consent.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. Severe/instable asthma:
A. FEV1 <70% predicted and/or FEV1/FVC <70;
B. Asthma exacerbation requiring prednisolon treatment, visit to a first aid station and/or hospitalisation in the preceding 12 months.
2. Specific IgE >= 0.7 kU/l to animals the patient is in daily contact with;
3. Immunotherapy in preceding 5 years;
4. Anatomical disorders of the nose;
5. Language barrier;
6. No daily access to internet (because of web based questionnaires);
7. Contraindications to immunotherapy (according to international guidelines).
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL2567 |
| NTR-old | NTR2692 |
| CCMO | NL25370.078.09 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd. |
| OMON | NL-OMON37299 |